Navigation Links
HeartWare Schedules Fourth Quarter Conference Call and Webcast
Date:2/19/2013

FRAMINGHAM, Mass. and SYDNEY, Feb. 19, 2013 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR, ASX:HIN) has scheduled a conference call to discuss its financial results for the three months ended December 31, 2012, at 8:30 a.m. U.S. Eastern Standard Time on Wednesday, February 27, 2013. The Company plans to release the financial results prior to the conference call.

The conference call with management will discuss the Company's financial results, highlights from the fourth quarter and business outlook.  The call may be accessed by dialing 1-888-846-5003 five minutes prior to the scheduled start time and referencing "HeartWare."  For callers outside the U.S., please dial +1-480-629-9856.

A live webcast of the call will also be available at the Company's website (www.heartware.com) by selecting "HeartWare Fourth Quarter 2012 Conference Call" under the section titled "Corporate Presentations" on the Home Page.  A replay of the conference call will be available through the above weblink immediately following completion of the call.

A copy of the news release announcing results and related information will be available on the Company's website, www.heartware.com.

About HeartWare International

HeartWare International develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat Class IIIB / IV patients suffering from advanced heart failure. The HeartWare® Ventricular Assist System features the HVAD® pump, a small full-support circulatory assist device designed to be implanted next to the heart, avoiding the abdominal surgery generally required to implant competing devices. The HeartWare System is approved in the United States for the intended use as a bridge to cardiac transplantation in patients who are at risk of death from refractory end-stage left ventricular heart failure, and has received CE Marking in the European Union and has been used to treat patients in 27 international countries. The device is also currently the subject of a U.S. clinical trial for destination therapy. For additional information, please visit the Company's website at www.heartware.com.

HeartWare International, Inc. is a member of the Russell 2000® and its securities are publicly traded on The NASDAQ Stock Market and the Australian Securities Exchange.

For further information:
Christopher Taylor
HeartWare International, Inc.
Email: ctaylor@heartwareinc.com
Phone: +1 508 739 0864


'/>"/>
SOURCE HeartWare International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HeartWare Stock Trading Halted Today; FDA Advisory Committee to Review HeartWare® Ventricular Assist System as a Bridge to Heart Transplantation
2. Heartware Schedules First Quarter Conference Call And Webcast
3. HeartWare Presentation at the Bank of America Merrill Lynch 2012 Health Care Conference to be Webcast
4. HeartWare Completes Enrollment In 450-Patient Pivotal Destination Therapy Clinical Trial
5. HeartWare International Receives CE Mark Addendum, Expanding Label to Include All Patients at Risk of Death From Refractory, End-Stage Heart Failure
6. HeartWare Names Peter F. McAree Chief Financial Officer
7. HeartWare Schedules Second Quarter Conference Call And Webcast
8. HeartWare Completes Acquisition Of World Heart Corporation
9. HeartWare Reports Second Quarter 2012 Results
10. HeartWare Presentation at the 2012 Wedbush PacGrow Lifesciences Management Access Conference to be Webcast
11. HeartWare Presentation At The Canaccord Genuity 32nd Annual Growth Conference To Be Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017  A new genetic test has been ... individuals who carry HLA-B*15:02 and who ... potentially deadly side effect of certain medications used ... HLA-B*15:02 is strongly associated with life-threatening ... and toxic epidermal necrolysis in patients treated with ...
(Date:3/23/2017)... ALBANY, New York , March 23, 2017 ... devices market exhibits a consolidated vendor landscape with the ... the overall market in 2015. These companies are ... Industries, Inc., Hygia Health Services, Inc., and VANGUARD ... global reprocessed medical devices market is witnessing the ...
(Date:3/23/2017)... BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage ... it has acquired Agalimmune Ltd., a private UK-based company with ... $6 million upfront payment, of which $3 million is in ... may be made based on development and commercial milestones. ... Agalimmune,s lead ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... 23, 2017 , ... The Wound Certification Prep Course ... Holdings, LLC, today announced that RestorixHealth® has officially endorsed WCPC as ... interested in becoming Certified Wound Specialist Physicians (CWSP®). , This collaborative effort ...
(Date:3/23/2017)... ... 23, 2017 , ... Altec Products, Inc. , a ... their 2016 Microsoft Dynamics Partner of the Year at DocLink Evolution , ... recognizes The Resource Group for their outstanding relationship with Altec and their ability ...
(Date:3/23/2017)... ... March 23, 2017 , ... Natural Subsistence, ... aspects of people’s health and nutrition, announced its product Leyzene is now available ... Subsistence develops nutritional supplements that help people improve all aspects of their health ...
(Date:3/23/2017)... ... March 23, 2017 , ... The ... facing life-altering and fatal diseases in opposition to the President’s Fiscal Year ... eviscerate care, services, and hope for the most vulnerable among us. , The ...
(Date:3/23/2017)... Marina del Rey, CA (PRWEB) , ... March ... ... version of its customizable coding audit software solution, iCode Assurance, at HCCA’s 21st ... iCode Assurance optimizes and accelerates the coding audit process for all medical chart ...
Breaking Medicine News(10 mins):